Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
20 lessons
11mOn November 9, 2026, FDA required a class-wide warning about NAION, a rare optic nerve condition that can cause sudden vision loss. The risk is real enough to label, small in absolute terms, and still debated. Here is the evidence, drug by drug.
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mSLU-PP-332 is a synthetic small molecule that activates estrogen-related receptors linked to exercise biology. Here is what the mouse studies actually show, and what is still unknown in humans.
9mGHK-Cu is a small copper-binding peptide with decades of lab research and a thin human record. Here's what it is, why topical and injectable use are different questions, and where FDA stands in 2026.
7mPatients ask about BPC-157 after extractions and implants. The dental literature is one rat periodontitis model, one rat oral-injury model, and three uncontrolled human cases. Here is each one.
6mWhat Cartalax (Ala-Glu-Asp, T-31) is, where its cartilage and anti-aging claims come from, what cell and rat studies found, and the missing human data.
6mAdamax is marketed as a modified Semax. Semax has decades of mostly Russian research. Adamax has essentially none in the published literature. Here's the honest comparison.
5mKPV is a three-amino-acid fragment of α-MSH studied for inflammation, mostly in the gut and mostly in mice. Here's what's known, what's claimed and what's missing.
10mCJC-1295 dose threads often ignore whether the vial is the albumin-binding DAC form or Mod GRF 1-29. The papers treat those as different exposure patterns. So should any educational chart.
9mThe new BPC-157 review is useful because it separates mechanism from marketing. The peptide looks biologically interesting, but the human evidence is still thin.
8mGLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
7mMOTS-c is a peptide encoded in your mitochondrial DNA that declines with age and mimics exercise benefits in animal studies. NAD+ has actual human clinical data. Here's what 2026 research shows about why these two molecules may work together — and what's still missing.
7mAfter 30+ years of animal research and 212 preclinical studies, BPC-157 has entered its first Phase 2 human trial. Here's what it will test, what it won't prove, and what to track.
9mFood thoughts, hunger and weight are different outcomes. Learn what human studies show about GLP-1 treatment and what returning food noise can—and cannot—tell you.
10mEpitalon is a lab-made four-amino-acid peptide based on a pineal gland extract. It lengthens telomeres in cell studies, but human evidence is small and old. It is not FDA approved, and since October 2026 it is one of six peptides in an HHS compounding policy.
9mTwo products share the CJC-1295 name. Learn what the Drug Affinity Complex changes, what the 2006 human studies actually measured, and why the no-DAC version has far less published evidence.
11mIGF-1 LR3 is a lab-modified copy of the IGF-1 hormone, built in 1992 as a research reagent. A 2026 review places it in the tier with no peer-reviewed human studies at all. It is not FDA approved, is regulated as a biologic rather than a peptide, and is prohibited in sport.
10mThe largest systematic review of BPC-157 to date analyzed 36 studies and confirmed consistent healing outcomes across tendons, ligaments, bone, and muscle tissue. Here's what the data shows.
9mMOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It has strong mouse data, one recruiting placebo-controlled human trial and no FDA approval. In October 2026 HHS added it to an interim compounding policy.
10mDevelop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.